Skip to main content

Advertisement

SpringerLink
Log in

Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes

  • Review Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Postoperative exacerbation of interstitial pneumonia in patients with interstitial lung disease and lung cancer has emerged as a serious problem. Therefore, we need to determine the risk factors for the development of postoperative exacerbation of interstitial pneumonia in this population. There are several subtypes of interstitial lung disease, which may lead to confusion about the treatment of patients with interstitial lung disease and lung cancer. Among the idiopathic forms of interstitial lung disease, we focused on idiopathic pulmonary fibrosis (IPF) and reviewed the surgical treatments used for patients with IPF and lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–68.

    PubMed  Google Scholar 

  2. Masuda M, Kuwano H, Okumura M, Amano J, Arai H, Endo S, Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery, et al. Thoracic and cardiovascular surgery in Japan during 2012: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2014;62:734–64.

    PubMed  PubMed Central  Google Scholar 

  3. Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–23.

    CAS  PubMed  Google Scholar 

  4. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304.

    Google Scholar 

  5. Saito A, Horie M, Micke P, Nagase T. The role of TGF-β signaling in lung cancer associated with idiopathic pulmonary fibrosis. Int J Mol Sci. 2018;19:3611.

    PubMed Central  Google Scholar 

  6. Ballester B, Milara J, Cortijo J. Idiopathic pulmonary fibrosis and lung cancer: mechanisms and molecular targets. Int J Mol Sci. 2019;20:593.

    CAS  PubMed Central  Google Scholar 

  7. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–61.

    PubMed  Google Scholar 

  8. Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D. Common pathogenic mechanisms between idiopathic pulmonary fibrosis and lung cancer. Chest. 2019;156:383–91.

    PubMed  Google Scholar 

  9. Kutlu CA, Williams EA, Evans TW, Pastorino U, Goldstraw P. Acute lung injury and acute respiratory distress syndrome after pulmonary resection. Ann Thorac Surg. 2000;69:376–80.

    CAS  PubMed  Google Scholar 

  10. Ruffini E, Parola A, Papalia E, Filosso PL, Mancuso M, Oliaro A, et al. Frequency and mortality of acute lung injury and acute respiratory distress syndrome after pulmonary resection for bronchogenic carcinoma. Eur J Cardiothorac Surg. 2001;20:30–6.

    CAS  PubMed  Google Scholar 

  11. Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K, Japanese Association for Chest Surgery, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147:1604–11.

    PubMed  Google Scholar 

  12. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.

    PubMed  PubMed Central  Google Scholar 

  13. Watanabe A, Miyajima M, Mishina T, Nakazawa J, Harada R, Kawaharada N, et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc Surg. 2013;61:254–61.

    PubMed  Google Scholar 

  14. Miura Y, Saito T, Tanaka T, Takoi H, Yatagai Y, Inomata M, et al. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir Investig. 2018;56:72–9.

    PubMed  Google Scholar 

  15. Yoo H, Jeong BH, Chung MJ, Lee KS, Kwon OJ, Chung MP. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2019;19:149.

    PubMed  PubMed Central  Google Scholar 

  16. Kawasaki H, Nagai K, Yokose T, Yoshida J, Nishimura M, Takahashi K, et al. Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. J Surg Oncol. 2001;76:53–7.

    CAS  PubMed  Google Scholar 

  17. Calabrese F, Lunardi F, Balestro E, Marulli G, Perissinotto E, Loy M, et al. Serpin B4 isoform overexpression is associated with aberrant epithelial proliferation and lung cancer in idiopathic pulmonary fibrosis. Pathology. 2012;44:192–8.

    CAS  PubMed  Google Scholar 

  18. Homma S, Sugino K, Sakamoto S. Usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Respir Investig. 2015;53:7–12.

    PubMed  Google Scholar 

  19. Sato T, Kondo H, Watanabe A, Nakajima J, Niwa H, Horio H, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg. 2015;63:164–7.

    PubMed  Google Scholar 

  20. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.

    PubMed  Google Scholar 

  21. Otsuka H, Sugino K, Hata Y, Makino T, Koezuka S, Isobe K, et al. Clinical features and outcomes of patients with lung cancer as well as combined pulmonary fibrosis and emphysema. Mol Clin Oncol. 2016;5:273–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Iyoda A, Jiang SX, Amano H, Ogawa F, Matui Y, Kurouzu N, et al. Prediction of postoperative exacerbation of interstitial pneumonia in patients with lung cancer and interstitial lung disease. Exp Ther Med. 2011;2:1073–6.

    PubMed  PubMed Central  Google Scholar 

  23. Chiyo M, Sekine Y, Iwata T, Tatsumi K, Yasufuku K, Iyoda A, et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg. 2003;126:1141–6.

    PubMed  Google Scholar 

  24. Kinoshita T, Azuma K, Sasada T, Okamoto M, Hattori S, Imamura Y, et al. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett. 2012;4:477–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013;85:326–31.

    CAS  PubMed  Google Scholar 

  26. Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, et al. Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer. 2013;82:260–5.

    PubMed  Google Scholar 

  27. Nagano T, Kotani Y, Fujii O, Demizu Y, Niwa Y, Ohno Y, et al. A case of acute exacerbation of idiopathic pulmonary fibrosis after proton beam therapy for non-small cell lung cancer. Jpn J Clin Oncol. 2012;42:965–9.

    PubMed  Google Scholar 

  28. Miyamoto T, Yamamoto N, Nishimura H, Koto M, Tsujii H, Mizoe JE, et al. Carbon ion radiotherapy for stage I non-small cell lung cancer. Radiother Oncol. 2003;66:127–40.

    PubMed  Google Scholar 

  29. Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society, et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018;56:268–91.

    PubMed  Google Scholar 

  30. Tanaka K, Tsutani Y, Wakabayashi M, Mizutani T, Aokage K, Miyata Y, Behalf of the Lung Cancer Surgical Study Group/Japan Clinical Oncology Group, et al. Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708, SURPRISE). Jpn J Clin Oncol. 2020;50:1076–9.

    PubMed  Google Scholar 

  31. Sato T, Watanabe A, Kondo H, Kanzaki M, Okubo K, Yokoi K, Japanese Association for Chest Surgery, et al. Long-term results and predictors of survival after surgical resection of patients with lung cancer and interstitial lung diseases. J Thorac Cardiovasc Surg. 2015;149:64–9.

    PubMed  Google Scholar 

  32. Sato S, Shimizu Y, Goto T, Kitahara A, Koike T, Ishikawa H, et al. Survival after repeated surgery for lung cancer with idiopathic pulmonary fibrosis: a retrospective study. BMC Pulm Med. 2018;18:134.

    PubMed  PubMed Central  Google Scholar 

  33. Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg. 2008;136:1357–63.

    PubMed  Google Scholar 

  34. Saito Y, Kawai Y, Takahashi N, Ikeya T, Murai K, Kawabata Y, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92:1812–7.

    PubMed  Google Scholar 

  35. Suzuki H, Sekine Y, Yoshida S, Suzuki M, Shibuya K, Yonemori Y, et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today. 2011;41:914–21.

    PubMed  Google Scholar 

  36. Mizuno Y, Iwata H, Shirahashi K, Takamochi K, Oh S, Suzuki K, et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41:e161–5.

    PubMed  Google Scholar 

  37. Iwata T, Yoshida S, Nagato K, Nakajima T, Suzuki H, Tagawa T, et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today. 2015;45:1263–70.

    PubMed  Google Scholar 

  38. Iwata T, Yoshida S, Fujiwara T, Wada H, Nakajima T, Suzuki H, et al. Effect of perioperative pirfenidone treatment in lung cancer patients with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2016;102:1905–10.

    PubMed  Google Scholar 

  39. Iwata T, Yoshino I, Yoshida S, Ikeda N, Tsuboi M, Asato Y, West Japan Oncology Group, et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE study). Respir Res. 2016;17:90.

    PubMed  PubMed Central  Google Scholar 

  40. Sekihara K, Aokage K, Miyoshi T, Tane K, Ishii G, Tsuboi M. Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis. Surg Today. 2020;50:905–11.

    CAS  PubMed  Google Scholar 

  41. Kanayama M, Mori M, Matsumiya H, Taira A, Shinohara S, Kuwata T, et al. Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis. Surg Today. 2020;50:469–74.

    PubMed  Google Scholar 

  42. Sakamoto S, Homma S, Mun M, Fujii T, Kurosaki A, Yoshimura K. Acute exacerbation of idiopathic interstitial pneumonia following lung surgery in 3 of 68 consecutive patients: a retrospective study. Intern Med. 2011;50:77–85.

    PubMed  Google Scholar 

  43. Watanabe A, Kawaharada N, Higami T. Postoperative acute exacerbation of IPF after lung resection for primary lung cancer. Pulm Med. 2011;2011:960316.

    PubMed  PubMed Central  Google Scholar 

  44. Furuya K, Sakamoto S, Takai Y, Sato N, Matsumoto K, Homma S. Acute exacerbation of idiopathic interstitial pneumonia after nonpulmonary surgery under general anesthesia: a retrospective study. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34:156–64.

    PubMed  PubMed Central  Google Scholar 

  45. Koyama K, Sakamoto S, Isshiki T, Shimizu H, Kurosaki A, Homma S. The activities of daily living after an acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2017;56:2837–43.

    PubMed  PubMed Central  Google Scholar 

  46. Isobe K, Kaburaki K, Kobayashi H, Sano G, Sakamoto S, Takai Y, et al. New risk scoring system for predicting acute exacerbation of interstitial pneumonia after chemotherapy for lung cancer associated with interstitial pneumonia. Lung Cancer. 2018;125:253–7.

    PubMed  Google Scholar 

  47. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, CAPACITY Study Group, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.

    CAS  PubMed  Google Scholar 

  48. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fbrosis. N Engl J Med. 2014;370:2083–92.

    PubMed  Google Scholar 

  49. Sakamoto S, Shimizu H, Isshiki T, Nakamura Y, Kurosaki A, Isobe K, et al. Effectiveness of pirfenidone for idiopathic pulmonary fibrosis associated with pleuroparenchymal fibroelastosis-like lesions and nonspecific interstitial pneumonia. Clin Respir J. 2020. https://doi.org/10.1111/crj.13292.

    Article  PubMed  Google Scholar 

  50. Sakamoto S, Muramatsu Y, Satoh K, Ishida F, Kikuchi N, Sano G, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology. 2015;20:445–52.

    PubMed  Google Scholar 

  51. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, INPULSIS Trial Investigators, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.

    PubMed  Google Scholar 

  52. Bronte G, Passiglia F, Galvano A, Barraco N, Listì A, Castiglia M, et al. Nintedanib in NSCLC: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8:188–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Fukunaga K, Yokoe S, Kawashima S, Uchida Y, Nakagawa H, Nakano Y. Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis. Respirol Case Rep. 2018;6:e00363.

    PubMed  PubMed Central  Google Scholar 

  54. Shiratori T, Tanaka H, Tabe C, Tsuchiya J, Ishioka Y, Itoga M, et al. Effect of nintedanib on non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: a case report and literature review. Thorac Cancer. 2020;11:1720–3.

    PubMed  PubMed Central  Google Scholar 

  55. Yamauchi Y, Izumi Y, Inoue M, Sugiura H, Goto T, Anraku M, et al. Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. PLoS ONE. 2011;6:e29053.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Kondoh Y, Azuma A, Inoue Y, Ogura T, Sakamoto S, Tsushima K, et al. Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis. A randomized, double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2020;201:1110–9.

    CAS  PubMed  Google Scholar 

  57. Isshiki T, Sakamoto S, Homma S. Therapeutic role of recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis. Medicina (Kaunas). 2019;55:172.

    Google Scholar 

  58. Isshiki T, Sakamoto S, Kinoshita A, Sugino K, Kurosaki A, Homma S. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration. 2015;89:201–7.

    CAS  PubMed  Google Scholar 

  59. Goto T, Maeshima A, Akanabe K, Oyamada Y, Kato R. Acute exacerbation of idiopathic pulmonary fibrosis of microscopic usual interstitial pneumonia pattern after lung cancer surgery. Ann Thorac Cardiovasc Surg. 2011;17:573–6.

    PubMed  Google Scholar 

  60. Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K, Homma S. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology. 2010;15:88–92.

    PubMed  Google Scholar 

  61. Sakamoto S, Shimizu H, Isshiki T, Sugino K, Kurosaki A, Homma S. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a historically controlled study. Respir Investig. 2018;56:136–43.

    PubMed  Google Scholar 

  62. Furuya K, Sakamoto S, Shimizu H, Sekiya M, Kinoshita A, Isshiki T, et al. Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respir Med. 2017;126:93–9.

    PubMed  Google Scholar 

  63. Fujimoto T, Okazaki T, Matsukura T, Hanawa T, Yamashita N, Nishimura K, et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication? Ann Thorac Surg. 2003;76:1674–8.

    PubMed  Google Scholar 

Download references

Funding

We have no funding for this manuscript.

Author information

Authors and Affiliations

  1. Division of Chest Surgery, Department of Surgery, School of Medicine, Toho University, 6-11-1, Omori-nishi, Ota-ku, Tokyo, 1438541, Japan

    Akira Iyoda, Yoko Azuma & Atsushi Sano

  2. Division of Respiratory Medicine, Department of Medicine, School of Medicine, Toho University, Ota-ku, Tokyo, Japan

    Susumu Sakamoto

  3. Department of Advanced and Integrated Interstitial Lung Diseases Research, School of Medicine, Toho University, Ota-ku, Tokyo, Japan

    Sakae Homma

Authors
  1. Akira Iyoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoko Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Susumu Sakamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sakae Homma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Atsushi Sano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akira Iyoda.

Ethics declarations

Conflict of interest

Department of Advanced and Integrated Interstitial Lung Diseases Research is an endowment department, supported with an unrestricted grant from Shionogi Company Limited, Chugai Pharmaceutical Company Limited, TEIJIN Pharma Limited, and Boehringer Ingelheim Japan Incorporated.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iyoda, A., Azuma, Y., Sakamoto, S. et al. Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes. Surg Today 52, 736–744 (2022). https://doi.org/10.1007/s00595-021-02343-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00595-021-02343-0

Keywords

Search

Navigation